Videos

Jacqueline Theis, OD, FAAO, stated that progressive lenses can exacerbate dizziness in her recent Academy 2025 lecture.

The core of Steen's presentation centers on the importance of managing patients with comorbid ocular conditions.

Brooke Messer, OD, FAAO, FSLS, details her session given with Mitch Ibach, OD, FAAO, during Academy 2025.

Sedgwick said that with the recent FDA authorization of Stellest lenses, he expects SightGlass to eventually find its niche in the US.

Jacqueline Theis, OD, FAAO, reminds eye care providers that all dry eye is neurological.

Pamela Theriot, OD, FAAO, said that eye care providers should aim to maintain optimal vision throughout their lifetime through proactive, comprehensive care.

Joseph Allen, OD, FAAO, Dipl ABO, detailed treatments for macular degeneration, ocular surface disease, dry eye, and potential myopia management during his presentation.

Discover how a new dry eye treatment offers rapid relief and long-term benefits for patients, transforming treatment approaches in eye care.

Julie Rodman, OD, MS, FAAO, details the complexities and nuances of diabetic retinopathy cases.

Chang discusses innovative approaches to fitting irregular corneas, enhancing vision for keratoconus patients through advanced scleral lens techniques.

Michelle Chung, OD, FAAO, FSLS, highlights the subtle signs of this progressive eye condition and the importance of differential diagnosis to prevent long-term vision loss.

Young explores the complex relationship between recreational drug use and eye health, highlighting addiction's impact on vision and patient care strategies.

Erin Rueff, OD, PhD, FAAO, details the best ways to stay up to date with dry eye developments and innovations.

Giovanna Olivares, OD, presented 2 posters on new data concerning the Acuvue Oasys Max 1-Day for Astigmatism contact lenses at the conference.

Contact Lens Institute (CLI) Visionary Shelby Brogdon, OD, breaks down recent CLI research and what it means for patient education and care.

Justin Schweitzer, OD, FAAO, details his presentation on dry eye innovations at the conference.

Raman Bhakhri, OD, FAAO, states that even if the statistics are normally against the chance of a life-threatening condition, the margins for error are slim.

Panelists discuss how cenegermin has opened the door for other companies to research neurotrophic keratitis (NK) treatments, with emerging therapies such as topical insulin and lacrimal gland injections showing promise.

Julie Rodman, OD, MS, FAAO, highlighted the critical role of advanced imaging technologies in eye care practices during an AAOpt 2025 presentation.

Raman Bhakhri, OD, FAAO, gives tips for identifying the root cause of optic neuritis.

Rueff, OD, PhD, FAAO, stated during her presentation that optometrists are not taking full advantage of their opportunities to suggest contact lenses to their patients with presbyopia.

Coats highlighted early patient education, simulation strategies, and optometry–ophthalmology collaboration during a session on toric lenses.

Jeffrey Walline, OD, PhD, said that the growing amount of CE sessions available is what sets the annual Academy meeting apart from other conferences.

Smith highlights advances in interventional glaucoma, including first-line SLT, emerging surgical options, and comanagement strategies, during the Ophthalmology Times and Optometry Times EyeCon 2025 conference.

Thomas A. Albini, MD; Rahul Tonk, MD, MBA; Alison Bozung, OD, FAAO; and Joseph Allen, OD, FAAO, Dipl ABO, weigh in on what they gained from the conference.

Panelists discuss how the key to successful neurotrophic keratitis (NK) management lies in thinking about the condition when reviewing patient history and making corneal sensitivity testing a routine part of ocular surface examinations.

Panelists discuss how they educate patients about neurotrophic keratitis (NK) using analogies such as "cut phone lines" to explain nerve damage and prepare patients for the 8-week treatment process and potential adverse effects.

Mark Bullimore, PhD, MCOptom, FAAO, like other ODs, is anxiously awaiting further clinical trial results.

Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO, will be joined by a handful of colleagues to discuss the latest in retina in Boston, Massachusetts, from October 8 to 11.